Foghorn Therapeutics Inc.

FHTX · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders14.1%

Institutions76.7%

Public / Other

Income Statement

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$22.60M	$34.16M	$19.23M	$1.32M	$430000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$102.68M	-$107.91M	-$117.14M	-$100.73M	-$68.53M
Operating income as a percentage of revenue.	-454.3%	-315.9%	-609.2%	-7637.1%	-15937.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$86.60M	-$98.40M	-$108.90M	-$101.30M	-$68.80M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-2.00	$-2.00	$-2.73	$-6.23
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-2.00	$-2.00	$-2.73	–

Balance Sheet

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$55.45M	$80.34M	$52.21M	$101.14M	$92.80M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$283.98M	$285.92M	$404.88M	$519.77M	$255.59M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	$0	$19.65M
Everything the company owes — debt, unpaid bills, and other obligations.	$329.51M	$363.11M	$404.77M	$422.90M	$109.41M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$45.53M	-$77.19M	$112000	$96.87M	$146.19M

Cash Flow Statement

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$100.41M	-$118.11M	$193.61M	-$50.25M	-$31.29M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$906000	$1.22M	$1.21M	$3.31M	$16.18M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$101.31M	-$119.33M	$192.40M	-$53.56M	-$47.47M

	You	Peer avg
Revenue Growth	+112.7%	-15.3%
ROE	–	-44.1%

Foghorn Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison